A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly

Huang, Lili; Wang, Ling; Li, Hong; Hu, Yuansheng; Ru, Wei-ping; Han, Weixiao; Su, Gang; Q, Ye; Han, Zhen; Xia, Jielai; Xia, Shengli; Xu, Miao; Li, Jing

doi:10.1080/21645515.2018.1509648

Cited by 9 publications

(9 citation statements)

References 19 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study assessed immunogenicity of PPSV23 in COPD patients and healthy controls and found that there were no statistically significant differences in the antibody GMCs between COPD patients and healthy controls ( 9 ). The 2-fold increase rates of 23 serotypes in this study were not lower than those in the Phase III licensure clinical trial of PPSV23 conducted in China ( 10 ).…”

Section: Discussioncontrasting

confidence: 67%

See 1 more Smart Citation

Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Chronic Obstructive Pulmonary Disease — Hebei Province, China, September−December, 2019

et al. 2021

China CDC Weekly

Self Cite

View full text Add to dashboard Cite

What is already known on this topic?The global burden of chronic obstructive pulmonary disease (COPD) is serious. Pneumococcal infection is associated with acute exacerbations of COPD (AECOPD).The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for COPD patients to decrease AECOPD due to pneumococcus, but evidence on the immunogenicity of PPSV23 in COPD patients is limited. What is added by this report?This study showed good immunogenicity of one dose of PPSV23 in COPD patients. Antibody levels against all 23 vaccine serotypes were assessed before and four weeks after vaccination of COPD patients with one dose of PPSV23. The percent of COPD patients who had two-fold increases in pneumococcal antibody levels following vaccination ranged from 65.2% (serotype 3) to 94.4% (serotype 2). There were statistically significant differences in immunogenicity by serotype. What are the implications for public health practice? This study supports current recommendations for PPSV23 vaccination of COPD patients in China to provide protection from pneumococcal diseases.

show abstract

Section: Discussioncontrasting

confidence: 67%

“…Finally, the study was short term and did not provide evidence of persistence of immunity. There are several studies reporting 1−2 years of immune persistence following PPSV23 vaccination of COPD patients (6)(7)9). Only one study reported long-term persistence (8).…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Chronic Obstructive Pulmonary Disease — Hebei Province, China, September−December, 2019

et al. 2021

China CDC Weekly

Self Cite

View full text Add to dashboard Cite

show abstract

“…As of August 8, 2023, more than 58 vaccines have been approved by WHO (Table 1), with more vaccines in clinical trials (Table 2). [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] These vaccines are produced by various platforms, encompassing inactivated, protein subunit, mRNA, and adenovirus vector vaccines (Fig. 1).…”

Section: Current Covid-19 Preventive and Therapeutic Strategies Curre...mentioning

confidence: 99%

Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period

Ao,

He,

Liu

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant casualties and put immense strain on public health systems worldwide, leading to economic recession and social unrest. In response, various prevention and control strategies have been implemented globally, including vaccine and drug development and the promotion of preventive measures. Implementing these strategies has effectively curbed the transmission of the virus, reduced infection rates, and gradually restored normal social and economic activities. However, the mutations of SARS-CoV-2 have led to inevitable infections and reinfections, and the number of deaths continues to rise. Therefore, there is still a need to improve existing prevention and control strategies, mainly focusing on developing novel vaccines and drugs, expediting medical authorization processes, and keeping epidemic surveillance. These measures are crucial to combat the Coronavirus disease (COVID-19) pandemic and achieve sustained, long-term prevention, management, and disease control. Here, we summarized the characteristics of existing COVID-19 vaccines and drugs and suggested potential future directions for their development. Furthermore, we discussed the COVID-19-related policies implemented over the past years and presented some strategies for the future.

show abstract

“…PCVs which have carrier protein conjugated to polysaccharide, induce B-cell memory response, and provide long-term immunity. 23valent PPV (PPSV23) showed robust immune response in adults >50 years and individuals 2-49 years having high risk or with chronic conditions (91,92). Efficacy of 13-valent PCV (PCV13) was observed among adults >65 years of age, in prevention of vaccine-type CAP and vaccine-type IPD which persisted till 4 years (96).…”

Section: Pneumococcal Vaccinesmentioning

confidence: 99%

Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco

Abouqal

Béji

Chakroun

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

Vaccine preventable diseases (VPDs) are a prevailing concern among the adult population, despite availability of vaccines. Unlike pediatric vaccination programs, adult vaccination programs lack the required reach, initiative, and awareness. Clinical studies and real-world data have proven that vaccines effectively reduce the disease burden of VPDs and increase life expectancy. In Tunisia and Morocco, the national immunization program (NIP) focuses more on pediatric vaccination and have limited vaccination programs for adults. However, some vaccination campaigns targeting adults are organized. For example, influenza vaccination campaigns prioritizing at risk adults which includes healthcare professionals, elderly, and patients with comorbidities. Women of childbearing age who have never been vaccinated or whose information is uncertain are recommended to receive tetanus vaccination. Tunisia NIP recommends rubella vaccine mainly for women of childbearing age, while in Morocco, national vaccination campaigns were organized for girls and women (up to 24 years of age) to eliminate rubella. Further, travelers from both countries are recommended to follow all requirements and recommendations in the travel destination. The objective of this manuscript is to provide an overview of the global disease burden of common VPDs including (but not limited to) meningococcal diseases, pneumococcal diseases, hepatitis, and influenza. The review also provides an overview of clinical data and guidelines/recommendations on adult vaccination practices, with special focus on Tunisia and Morocco. Some European and North American countries have concrete recommendations and strategies for adult vaccination to keep the VPDs in check. In Morocco and Tunisia, although, there are sporadic adult vaccination initiatives, the efforts still need upscaling and endorsements to boost vaccination awareness and uptake. There is a need to strengthen strategies in both countries to understand the disease burden and spread awareness. Additional studies are needed to generate economic evidence to support cost-effectiveness of vaccines. Integration of private and public healthcare systems may further improve vaccination uptake in adults.

show abstract

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly

Cited by 9 publications

References 19 publications

Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Chronic Obstructive Pulmonary Disease — Hebei Province, China, September−December, 2019

Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Chronic Obstructive Pulmonary Disease — Hebei Province, China, September−December, 2019

Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period

Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco

Contact Info

Product

Resources

About